Barlam Tamar F, Gupta Kalpana
Associate Professor of Medicine at the Boston University School of Medicine. She is a member of the Infectious Disease section at the Boston Medical Center where she directs antibiotic stewardship efforts.
Professor of Medicine at the Boston University School of Medicine and Chief of Infectious Diseases at VA Boston Healthcare System. She has a research program on detection, treatment and prevention of multidrug-resistant pathogens.
J Law Med Ethics. 2015 Summer;43 Suppl 3:12-6. doi: 10.1111/jlme.12268.
Antibiotic-resistant (ABR) bacteria develop when bacteria are exposed to antibiotics either during treatments in humans or animals or through environmental sources contaminated with antibiotic residues. Resistant bacteria selected by medical, agricultural, and industrial use spread globally through international travel, the export of animals and retail products, and the environment. It is essential that nations work together to identify how to reduce emergence and amplification of resistant bacteria through sensible antibiotic treatment guidelines and restrictions, concerted efforts for surveillance, and infection control.
当细菌在人类或动物治疗期间或通过被抗生素残留污染的环境来源接触到抗生素时，就会产生抗生素耐药（ABR）细菌。由医疗、农业和工业用途选择出的耐药细菌通过国际旅行、动物和零售产品出口以及环境在全球传播。各国必须共同努力，通过合理的抗生素治疗指南和限制措施、协同监测努力以及感染控制，确定如何减少耐药细菌的出现和扩散。
